Levemir 101: A Plain-English Guide for 2026

Levemir at a glance:

• Drug class: Long-acting basal insulin analog
• Manufacturer: Novo Nordisk
• FDA approved: 2005
• Route: subcutaneous injection (FlexPen)
• Typical frequency: once or twice daily
• Half-life: ~5–7 hours (duration of action 12–24 hours, dose-dependent)
• Cash price (US): Discontinued in US; previous list was ~$330/month

Most people land on a Levemir page because they're weighing it against another option, trying to manage side effects, or trying to figure out if it's worth the money. We try to answer all three honestly here. The headline: Basal insulin coverage with somewhat less weight gain than NPH or glargine in some studies.

What is Levemir?

Insulin detemir binds reversibly to albumin via a fatty acid side chain, prolonging its action. Duration is dose-dependent (~12–20 hours).

Levemir is manufactured by Novo Nordisk. Levemir was approved by the FDA in 2005. Its approved indications include type 1 diabetes, type 2 diabetes. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class long-acting basal insulin analog works by targeting specific receptor pathways. Here's what to expect.

How Levemir Works in the Body

Insulin detemir binds reversibly to albumin via a fatty acid side chain, prolonging its action. Duration is dose-dependent (~12–20 hours). The receptor target — compound-specific — drives the downstream effects users care about: basal insulin coverage with somewhat less weight gain than nph or glargine in some studies.

The pharmacokinetics matter for daily use. Levemir has a half-life of ~5–7 hours (duration of action 12–24 hours, dose-dependent), which determines how often it is dosed. The standard route of administration is subcutaneous injection (FlexPen), and the typical schedule is once or twice daily.

For more detail on the underlying biology, see our breakdown of how Levemir works.

Who Uses Levemir?

Levemir is most relevant for people whose situation maps to its approved indications: type 1 diabetes; type 2 diabetes.

People who should avoid Levemir include those with the following:

• Note: Novo Nordisk discontinued Levemir in the US at the end of 2024.

Common and Serious Side Effects

The most commonly reported side effects of Levemir include:

• hypoglycemia
• injection-site reactions

Serious risks — uncommon but worth knowing — include:

• severe hypoglycemia

We have a more detailed breakdown in our Levemir side-effects guide.

Levemir vs Alternatives

Lantus (glargine), Tresiba (degludec), and biosimilars are the primary substitutes. If you are weighing Levemir against another option, our comparison pages include Levemir Side Effects Decoded: What's Normal vs. What Isn't, What Results Should You Expect from Levemir? A Practical Guide, Levemir Cost in 2026: What You'll Actually Pay (Real Numbers).

Bottom Line

Treat Levemir as one tool among several. The most successful users we see treat it as part of a structured approach, not a standalone fix. Multiple randomized controlled trials support its efficacy. If you are considering Levemir, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Levemir Side Effects Decoded: What's Normal vs. What Isn't
• What Results Should You Expect from Levemir? A Practical Guide
• Levemir Cost in 2026: What You'll Actually Pay (Real Numbers)
• Levemir Cycle Guide: Published Research vs. Online Protocols
• Is Lantus Right for You? An Evidence-Based Breakdown
• What Is Humalog? Everything You Should Know Before Starting

Sources

• American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care 2024;47(Suppl 1).
• Heise T et al. Insulin Pharmacokinetics and Pharmacodynamics. Diabetes Obes Metab 2017;19:3.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.